Using the Freestyle Libre Pro iQ Sensor to Predict Cardiovascular Outcomes in Adults with Acute Coronary Syndrome

What this Trial Is About

Disorders of blood sugar control are common in patients hospitalized for acute coronary syndrome ACS, with abnormal glucose levels found in about half of cases. High blood sugar is a major factor affecting outcomes after ACS, regardless of diabetes status. This research aims to evaluate the predictive value of various glucose measurements taken by a continuous glucose monitor over two weeks in patients with ACS. Participants will have the Freestyle Libre Pro iQ sensor applied upon admission to the cardiac intensive care unit. This device continuously and non-invasively measures interstitial glucose levels for up to 14 days. If necessary, a replacement sensor will be placed during hospitalization. The study focuses on the glucose data collected by this sensor and how it relates to cardiovascular events over one year. During the study, participants will be monitored using the sensor while receiving standard ACS care. Researchers will track cardiovascular events for 12 months and diabetes status at 2 and 12 months. The study collects detailed glucose variability data to assess its ability to predict major cardiovascular outcomes. Participation involves wearing the sensor during hospitalization and follow-up assessments over a year to evaluate health outcomes.

Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS